Skip to main content
Clinical Trials/NCT03113721
NCT03113721
Unknown
N/A

Prospective, Non-interventional, Multi-centre Clinical Study to Assess the Clinical Validity of the HBP Assay to Predict Development of Severe Sepsis in Patients With Suspected Infection Following ED Admission

Axis Shield Diagnostics Ltd5 sites in 1 country571 target enrollmentMarch 27, 2017

Overview

Phase
N/A
Intervention
Not specified
Conditions
Sepsis
Sponsor
Axis Shield Diagnostics Ltd
Enrollment
571
Locations
5
Primary Endpoint
Measurement of plasma levels of HBP to evaluate patients with suspected infection for their risk of developing severe sepsis
Last Updated
7 years ago

Overview

Brief Summary

The purpose of this prospective, non-interventional, multi-centre clinical study is to assess the clinical validity of the Heparin Binding Protein (HBP) assay for indicating the presence, or outcome, of severe sepsis (including septic shock), over 72 hours, in patients with suspected infection following emergency department admission.

Detailed Description

The primary objective of this study is to use HBP concentration to indicate the presence, or outcome, of severe sepsis (including septic shock) at admission and to predict the outcome of severe sepsis (including septic shock) over 72 hours, in patients with suspected infection following emergency department admission. The secondary objectives of this study are to separately evaluate the performance of HBP concentration to a) indicate the presence of severe sepsis (including severe sepsis) at admission and b) to predict the outcome of severe sepsis (including septic shock) over 72 hours, in patients with suspected infection following emergency department admission. Further exploratory objectives include evaluating the use of HBP measurement to indicate the outcome of severe sepsis (including septic shock) in patients with suspected infection 12-24 hours after emergency department admission, to compare the use of HBP to other markers of severe infection and to evaluate whether or not different cut-off values are required for the progression and outcome measures.

Registry
clinicaltrials.gov
Start Date
March 27, 2017
End Date
March 1, 2019
Last Updated
7 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Axis Shield Diagnostics Ltd
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • \>18 years of age, suspected infection

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Measurement of plasma levels of HBP to evaluate patients with suspected infection for their risk of developing severe sepsis

Time Frame: 72 hours

The purpose of this measurement is to assess the clinical validity of plasma levels of HBP for indicating the presence, or outcome, of severe sepsis (including septic shock), over 72 hours, in patients with suspected infection following emergency department admission. The concentration of plasma HBP will be compared to the final clinical outcome of the patient to assess the ability of the HBP level to predict clinical progression.

Study Sites (5)

Loading locations...

Similar Trials